Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer

Oncology

Volumn 69, Issue SUPPL. 3, 2005, Pages 17-24

  Hurwitz, Herbert ^a   Kabbinavar, Fairooz ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

5 fluorouracil; Bevacizumab; Capecitabine; Colorectal cancer; Fluoropyrimidine; Irinotecan; Oxaliplatin

Indexed keywords

ANTHRACYCLINE; ANTIHYPERTENSIVE AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; DOXORUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PACLITAXEL; TAXANE DERIVATIVE;

AREA UNDER THE CURVE; ARTERY THROMBOSIS; ASTHENIA; BLEEDING; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE EXACERBATION; DRUG APPROVAL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FEVER; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HUMAN; HYPERTENSION; LEUKOPENIA; METASTASIS; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RASH; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SOLID TUMOR; THROMBOEMBOLISM; TUMOR BLEEDING;

EID: 27944458472     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088480     Document Type: Review

References (30)

1. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
2. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000;355:1041-1047.
3. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.
4. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Brand F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
5. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-147.
6. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
7. Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, Graeven U, Lokich J, Madajewicz S, Maroun JA, Marshall JL, Mitchell EP, Perez-Manga G, Rougier P, Schmiegel W, Schoelmerich J, Sobrero A, Schilsky RL: Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004;90:1190-1197.
8. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schilsky RL: First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002;13:566-575.
9. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
10. Shepherd FA, Pereira J, Ciuleanu TE, Tan EH, Hirsh V, Thongprasert S, Bezjak A, Tu D, Santabarbara P, Seymour L: A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. J Clin Oncol 2004;22(suppl):abstract 7022.
11. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-844.
12. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-4599.
13. Gordon MS, Margolin K, Talpaz M, Sledge GWJ, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843-850.
14. Kaelin WG Jr: The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 2004;10:6290S-6295S.
15. Margolin K, Gordon MS, Holmgren E, Gaudreault J, Novotny W, Fyfe G, Adelman D, Stalter S, Breed J: Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data. J Clin Oncol 2001;19:851-856.
16. Langmuir VK, Cobleigh MA, Herbst RS, Holmgren E, Hurwitz H, Kabbinavar F, Miller K, Novotny W: Successful long-term therapy with bevacizumab (Avastin) in solid tumors. Proc Am Soc Clin Oncol 2002;21 abstract 32.
17. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
18. Fyfe GA, Hurwitz H, Fehrenbacher L, Cartwright T, Cartwright J, Heim W, Berlin J, Kabbinavar F, Holmgren E, Novotny W: Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups. J Clin Oncol 2004;22(suppl):abstract 3617.
19. Hedrick EE, Hurwitz H, Sarkar S, Griffing S, Novotny W, Grothey A: Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC). J Clin Oncol 2004;22(suppl):abstract 3517.
20. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-65.
21. Skillings JR, Johnson DH, Miller K, Kabbinavar F, Bergsland E, Holmgren E, Holden SN, Hurwitz H, Scappaticci F: Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. J Clin Oncol 2005;23(suppl):196s (abstract 3019).
22. Kozloff M, Cohn A, Christiansen A, Flynn P, Kabbinavar F, Robles R, Ulcickas Yood M, Sarkar S, Hambleton J, Grothey A: Safety of bevacizumab (BV) among patients (pts) receiving first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): preliminary results from a large registry in the US. J Clin Oncol 2005;23(suppl):262s (abstract 3566).
23. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 2005;23:3697-3705.
24. Mass RD, Fyfe G, Hambleton J, Kabbinavar F, Hurwitz H, Novotny W, Sarkar S: Bevacizumab in combination with 5-FU/leucovorin improves survival in patients with metastatic colorectal cancer: A combined analysis. J Clin Oncol 2004;22(suppl):abstract 3616.
25. Shen BQ, Stainton S, Li D, Pelletier N, Zioncheck TF: Combination of Avastin™ and Xeloda® synergistically inhibits colorectal tumor growth in a COLO205 tumor xenograft model. Proc Am Assoc Cancer Res 2004;45:508 (abstract 2203).
26. Maung K: Capecitabine/bevacizumab compared to capecitabine alone in pretreated metastatic breast cancer: results of a phase III study. Clin Breast Cancer 2003;3:375-377.
27. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris AL: Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57:963-969.
28. Hochster HS, Welles L, Hart L, Ramanathan RK, Hainsworth J, Jirau-Lucca F, Shpilsky A, Griffing S, Mass R, Emanuel D: Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 studies. J Clin Oncol 2005;23(suppl):249s (abstract 3515).
29. Giantonio BJ, Catalano PJ, Meropol NJ, O'DwyerPJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB: High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol 2005;23(suppl):1s (abstract 2).
30. Fernando N, Yu D, Morse M, Blobe G, Odogwu L, Crews J, Polito A, Honeycutt W, Franklin A, Hurwitz H: A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer. J Clin Oncol 2005;23(suppl):260s (abstract 3556).